# Single Ascending Doses of HER-096 in Healthy Subjects

> **NCT05915247** · PHASE1 · COMPLETED · sponsor: **Herantis Pharma Plc.** · enrollment: 60 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** HER-096
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05915247
- **Lead sponsor:** Herantis Pharma Plc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-29
- **Primary completion:** 2023-09-29
- **Final completion:** 2023-09-29
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2023-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05915247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05915247, "Single Ascending Doses of HER-096 in Healthy Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05915247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*